Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

NEOPLATIN - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/NEOPLATIN

Approved

STANDARD

NEOPLATIN

Zee Laboratories Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 7aa66846e9f3c5b4
Company: Zee Laboratories Limited
Type: Standard

Approval Details

Approval Id: 7aa66846e9f3c5b4
Drug Approval Philippines Name: NEOPLATIN
Product Name: NEOPLATIN
Registration Number: DR-XY42670
Brand Name: NEOPLATIN
Generic Name: CISPLATIN
Dosage Form: Solution For Injection
Dosage Strength: 1 mg/mL
Manufacturer: Zee Laboratories Limited
Importer: Eon Pharmatek, Inc.
Distributor: Eon Pharmatek, Inc.
Issuance Date: 24 January 2024
Expiry Date: 06 January 2029
Pharmacologic Category: ANTINEOPLASTIC
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

7aa66846e9f3c5b4

Type

Standard

Back to Philippines FDA Approvals